-
Vaccinations do not raise risk of multiple sclerosis
02 Aug 2019 16:42 GMT
A large study has concluded that vaccinations are not a risk factor for multiple sclerosis. Instead, the findings reveal a consistent link between higher vaccination rates and a lower likelihood of developing the disabling condition.
Researchers at the …
-
Genentech to Present New OCREVUS (Ocrelizumab) Data Analyses Showing Significant Reduction of Disability Progression in Relapsing and Primary Progressive Multiple Sclerosis at the AAN Annual Meeting
08 May 2019 07:16 GMT
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--May 8, 2019--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced new OCREVUS ® (ocrelizumab) data in relapsing and primary progressive multiple sclerosis (MS) were presented at …
-
Global Therapeutic Vaccines Market Insights Report 2019-2023: Rising Incidence & Prevalence of Diseases and Strong Therapeutic Vaccine Pipeline Will Provide Significant Growth Opportunities
28 Jun 2019 13:54 GMT
Dublin, June 28, 2019 (GLOBE NEWSWIRE) -- The "Global Therapeutic Vaccines Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.
Global Therapeutic Vaccines Market expected to grow at a CAGR of more than 19% during the …
-
Tonix Pharmaceuticals and Massachusetts General Hospital Enter into Research Collaboration to Develop Tonix’s Third Generation Anti-CD154 Monoclonal Antibody, TNX-1500, for the Treatment and Prevention of Organ Transplant Rejection
21 Aug 2019 11:00 GMT
NEW YORK, Aug. 21, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the signing of a research collaboration agreement with Massachusetts General …
-
FDA approves new oral treatment for multiple sclerosis
30 Mar 2019 09:06 GMT
The U.S. Food and Drug Administration today approved Mavenclad (cladribine) tablets to treat relapsing forms of multiple sclerosis (MS) in adults, to include relapsing-remitting disease and active secondary progressive disease. Mavenclad is not recommended …
-
FDA approves new oral drug to treat multiple sclerosis
27 Mar 2019 06:26 GMT
The U.S. Food and Drug Administration today approved Mayzent (siponimod) tablets to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease …
-
Researchers Find A Web Of Factors Behind Multiple Sclerosis
21 Jan 2019 13:38 GMT
A scanning electron micrograph shows microglial cells (yellow) ingesting branched oligodendrocyte cells (purple), a process thought to occur in multiple sclerosis. Oligodendrocytes form insulating myelin sheaths around nerve axons in the central nervous …
-
Researchers identify promising therapeutic option to treat multiple sclerosis
14 Jan 2019 11:54 GMT
With funding provided by the German Research Foundation (DFG) for the Collaborative Research Center/Transregio 128, researchers at the Medical Center of Johannes Gutenberg University Mainz (JGU) identified an innovative and promising therapeutic option …
-
Atara Biotherapeutics Announces Publication of Phase 1 Study Demonstrating Clinical Improvement in Progressive Multiple Sclerosis Patients Treated with ATA190, an Autologous Epstein-Barr Virus (EBV)-Specific T-Cell Immunotherapy
19 Nov 2018 13:30 GMT
SOUTH SAN FRANCISCO, Calif., Nov. 19, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, …
-
Michael Klein: Talking with the vaccine-hesitant and vaccine-deniers
17 Mar 2019 03:53 GMT
… unearthed by the vaccine-deniers include a … conspiracy theorists.
Serious vaccine-deniers regularly cite research … like multiple sclerosis, Parkinsonism, Alzheimer’s and autism.
The Vaccine-Hesitant … to discharge vaccine-hesitant and vaccine-deniers from …
About
© 1995-2019